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Abstract
Rheumatoid arthritis is one of the commonest autoimmune dis-
eases. It is a chronic, progressive, systemic inflammatory disorder 
affecting the synovial joints and typically producing symmetrical 
arthritis. If left untreated, it leads to joint destruction and thus de-
formity and disability. In the recent years, advances in molecular 
biology have led to a variety of new treatment approaches to rheu-
matoid arthritis and other systemic inflammatory diseases associ-
ated with autoimmunity. Anti tumor necrosis factor (TNF) agents 
are emerging in the frontline management of rheumatoid arthritis 
(RA) in the current era of biological treatment. We presented a 
46-year-old Chinese female with a history of seropositive RA for 
the past 22 years refractory and intolerant to multiple medications 
including sulphasalazine (SSZ), leflunomide, hydroxychloroquine 
(HCQ) and methotrexate (MTX), thus infliximab, a tumor necro-
sis factor (TNF) inhibitor was initiated. However, despite receiving 
6 cycles of infliximab therapy, she still complained of persistent 
disabled multiple joint pain and swelling. This report will discuss 
about rheumatoid arthritis, which is refractory to infliximab (a TNF 
inhibitor) and its alternative.
Keywords:  Rheumatoid arthritis; Biologics treatment; Tumor-
necrosis factor inhibitor; Infliximab
Introduction
Rheumatoid arthritis (RA) is a chronic, progressive, de-
structive and disabling disease that primarily affects the pe-
ripheral joints. The joint involvement is symmetrical, may 
be remitting, but if uncontrolled may lead to destruction of 
joints due to erosion of cartilage and bone which leads to 
deformity. Approximately 15% of people with RA have a 
particularly severe form of the disease that manifests itself 
as unremitting pain and swelling, causing severe disability 
and loss of function [1].
Drug therapy for RA has developed and evolved from 
empirical relief of symptoms with non-steroidal anti-inflam-
matory drugs (NSAIDS) to targeted intervention in the im-
munoinflammatory process with tumor necrosis factor inhib-
itors. Biologic DMARDs, produced by recombinant DNA 
technology, generally target cytokines or their receptors 
or are directed against other cell surface molecules. These 
include anticytokine therapies, such as the TNF inhibitors: 
etanercept, infliximab and adalimumab,  the interleukin-1 
receptor antagonist, anakinra, and other biologic response 
modifiers such as abatacept (CTLA4-Ig) and anti-CD20 B-
cell depleting monoclonal antibody, rituximab [2, 3].
Case Report
This is a case of 46-year old Chinese lady who has been 
suffering from seropositive rheumatoid arthritis since 
1987. During the earlier years, she was treated with daily 
oral chloroquine and indomethacin, an NSAIDS. However 
she was lost to follow-up after about a year. She presented 
again to our rheumatology clinic in 1992 with polyarthri-
tis and early morning stiffness. The patient had received 
multiple  DMARDs  therapies  including  oral  methotrexate 
(MTX), sulphasalazine (SSZ), hydroxychloroquine (HCQ), 
leflunomide, and intermittent short course of oral prednis-
olone. However the medication was inadequate to control 
the symptoms as she still experienced occasional disturbing 
joints pain and she was unable to tolerate the gastrointesti-
nal discomfort from high dose of SSZ. She also complained 
of mild itchiness on taking leflunomide and hydroxychloro-
quine. The dose of these medications was adjusted through-
out the follow-up.
In December 2006, the patient was on oral leflunomide 
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20 mg/day, oral SSZ 1 g thrice a day and oral HCQ 200 mg/
day when she complained of persistent multiple joints pain 
and swelling for more than six months. She then was planned 
for a tumor necrosis factor-α (TNF-α), infliximab therapy; 
however it was delayed until her first infliximab infusion in 
March 2009 due to financial settlement from welfare sup-
port. 
During this waiting period, she was bridged with low 
dose of oral prednisolone (5 mg/day ) and oral MTX (7.5 mg 
weekly) was reintroduced in end of 2008. MTX was stopped 
initially due to suspected lung fibrosis, however high resolu-
tion computed tomography (HRCT) scan of thorax was done 
in May 2007 showed no evidence of lung fibrosis. Her oral 
MTX was optimized to 10 mg weekly during her first inflix-
imab therapy. She received 155mg (3mg per kg) of intrave-
nous infliximab infusion without any adverse reaction. Prior 
to this treatment, her visual analogue score (VAS) for her 
joint pain was 10/10. 
She was planned for further six weekly infusions of to-
tal six cycles, however her fifth cycle of infusion was de-
ferred as she had flare of polyarthritis with chest infection. 
The chest x-ray showed pneumonic changes over left lower 
zone. The patient was treated with intravenous antibiotic 
ceftriaxone and oral MTX was withheld. Oral prednisolone 
was increased to 15 mg/daily upon discharge. Her fifth cycle 
of infliximab infusion was given two weeks later. However, 
during the administration, she still complained of disturbing 
left elbow and right knee pain and swelling. 
During her admission for 6th  infliximab infusion in No-
vember 2009, the patient claimed her left elbow and right knee 
were still painful and swollen, restricting her daily activity. 
Her pain was slightly relieved by daily analgesic (meloxicam 
7.5 mg). She gave VAS of 8/10 for the pain. However, she 
denied early morning stiffness or numbness and assured that 
she has been compliant to her oral DMARDs. She denied of 
any respiratory symptoms.
On examination, she was alert and pink, her blood pres-
sure was 120/70 mmHg, pulse rate 86 beats per minute and 
afebrile.  Her  cardiovascular  and  abdominal  examinations 
were normal, but lungs examination revealed fine crackles at 
left lower zone. Musculoskeletal assessment showed warm 
and tenderness of the first and second left metocarpophalan-
geal joints and mildly swollen second and third right meto-
carpophalangeal joints. Her left wrist, left elbow and knee 
joints were swollen, warm and tender. Her disease activity 
score (DAS28) was 5. 
Laboratory evaluation revealed a positive rheumatoid 
factor, erythrocyte sediment rate and C-reactive protein were 
62 mm/hour and 2.56 mg/l respectively. Total white count 
was 6.6 x109/L , hemoglobin 11.2 g/dL and platelet  295 
x 109/L. Liver function test and renal profile were normal. 
Chest X-rays showed minimal right apical pleural thicken-
ing. MTX was not restarted in view of possibility of pulmo-
nary fibrosis. Repeat HRCT of thorax and lung function test 
were arranged.
In view of insufficient response to infliximab, this pa-
tient was planned for adalimumab therapy, another TNF-in-
hibitor. During subsequent follow-up in rheumatology clinic, 
this patient had swollen hands and knees with DAS 28 score 
of 5.06. Currently this patient is waiting for financial approv-
al from welfare support for adalimumab treatment.
Discussion
  
Researches have led to a better understanding of the biol-
ogy and pathogenesis of the disease. The pathogenesis of 
RA starts with T cell activation, which subsequently leads 
to multiple effects including activation and proliferation of 
synovial lining and endothelial cells, recruitment and acti-
vation of additional pro-inflammatory cells from the bone 
marrow and circulation, secretion of cytokines and proteases 
by macrophages and fibroblast-like synovial cells, and auto-
antibody production [1].
The aims of management for patients with RA are to 
prevent early damage of the joints, improve symptoms and 
restore the patient to normal non-RA status. The prolonged 
complete control of the abnormal inflammatory process is 
the fundamental goal [2, 3]. This is important as joint dam-
age occurs early in the course of rheumatoid arthritis; 30 per-
cent of patients have radiographic evidence of bony erosions 
at the time of diagnosis, and this proportion increases to 60 
percent by two years [4]. 
This patient was treated with infliximab for six cycles. 
Infliximab is a chimeric mouse or human anti-TNF-α mono-
clonal antibody, the first agent generated to selectively tar-
get TNF-α, which has been shown to be effective for RA. 
Lipsky et al 2000 had done a double-blind, placebo-con-
trolled, randomized trial of 428 patients in Anti-Tumor ne-
crosis factor Trial in Rheumatoid Arthritis with Concomitant 
Therapy (ATTRACT). The patients with active RA despite 
MTX therapy received placebo with MTX (MTX-only) or 
infliximab 3 mg/kg or 10 mg/kg every four or eight weeks 
with MTX (infliximab plus MTX) for 102 weeks. The result 
showed that infliximab plus MTX augments clinical and ra-
diographic benefit in patients with active RA despite receiv-
ing treatment with MTX [5, 7].
However, multiple studies have documented that pa-
tients seldom continue therapy for more than five years with 
current DMARDs because of loss of efficacy or intolerable 
side effects [8, 9]. This patient had tried multiple anti-rheu-
matic medications, however their usefulness was limited due 
to side effects or lack of efficacy. She was still in active ar-
thritis despite combination of DMARDs. 
In the recent years, TNF is found to be a principle cyto-
kine in the pathogenesis of RA. This has contributed in the 
development of agents that block these cytokines or their ef-
fects. TNF inhibitors are one of the most important advances 
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in the history of the treatment of this disorder that include 
etanercept, infliximab, and adalimumab [10].
Infliximab when combined with MTX inhibits the pro-
gression of structural damage in patients with early RA dur-
ing the two year period of treatment in the trial. Early inter-
vention with infliximab in patients with active RA despite 
MTX therapy may provide long term benefits by preventing 
radiographic progression and preserving joint integrity. Inf-
liximab is given by intravenous infusion at a dose of 3 mg/
kg body weight at 0, 2 and 6 weeks and at 8-weekly intervals 
thereafter [11, 12]. 
In this case, the MTX was discontinued while on inf-
liximab treatment due to pulmonary toxicity. Clinical trials 
have confirmed both the efficacy and tolerability of the agent 
when used in patients with DMARD refractory RA, both 
alone and in combination with MTX [11, 12]. Sixty percent 
of patients receiving infliximab, with or without MTX, expe-
rienced at least 20% improvement in disease activity. Impor-
tantly, co-administration of low dose MTX significantly pro-
longed the duration of response seen with low dose (1 mg/
kg) infliximab. Co-administration of MTX with higher doses 
of infliximab (3 and 10 mg/kg) also prolonged response du-
ration, although not statistically significantly [11]. 
However, despite treated with infliximab, the patient is 
still having persistent active disease. Although the therapeu-
tic effects of anti-TNF agents are superior to conventional 
DMARDs, there are still nonresponders. Treatment should 
be withdrawn if response is not adequate within 6 months (as 
defined by an improvement in DAS28 score of more than 1.2 
points) or if response is not maintained [13]. 
Laken et al have first reported the formation of inflix-
imab–anti-infliximab complexes during infliximab infusion 
in non-responders with rheumatoid arthritis. The non-re-
sponders had high human anti-chimeric antibodies (HACAs) 
level measured by using radio-labelled infliximab, but low 
or not detectable in responders. High levels of HACAs are 
also most probably responsible for infusion reactions to in-
fliximab [14].  Beart et al also found a shorter duration of 
response to infliximab with the presence of anti-infliximab 
level in patients with Crohn’s disease [15].
The development of HACA is detected in 40%  of pa-
tients when infliximab is used alone, but is significantly re-
duced by an uninterrupted course of infliximab at doses of   
no less than 3 mg/kg and by co-administration of methotrex-
ate [15].  Data have linked HACA to the development of 
infusion reactions, but it is less clear that HACA are respon-
sible for the blunting of clinical responses to infliximab that 
occur with regular administration over time [15]. The im-
munogenicity of infliximab was reduced by the combination 
infliximab with high-dose MTX and it is effective and safe in 
long-term treatment up to 54 weeks. Infliximab in combina-
tion with MTX may be an optimal therapeutic regimen for 
patients with severe RA [15].
Navarro et al showed that lack of response to a first TNF 
antagonist does not predict the response to a second one, yet 
the efficacy of a second TNF antagonist is inferior to that of 
the first [16].  Finckh et al did an observational study that 
suggested patients with RA who have stopped a previous 
TNF inhibitor treatment because of ineffectiveness, chang-
ing to rituximab is more effective than switching to an alter-
native TNF inhibitor [17].  As for the latest National Institute 
and Health and clinical excellence (NICE) guideline stated 
that for secondary non-responders, a second TNF should be 
allowed, but the primary non-responders would be better at 
that stage to try a biologic with a different mechanism of ac-
tion [18, 19].
This patient is considered as a secondary non-respond-
er as she had some improvement of arthritis in the earlier 
course of the infliximab treatment. Next plan in this patient is 
adalimumab therapy. Adalimumab, another TNF-inhibitor, is 
a recombinant human IgG1 monoclonal antibody that binds 
to human TNF with high affinity, both impairing cytokine 
binding to its receptors and lysing cells that express TNFon 
their surface. It is administered 40 mg SC every 2 weeks 
[18-21].
Rituximab is a chimeric B cell depleting monoclonal 
anti-CD20 antibody.  It exerts its effect by binding to CD20 
on B cells and causing cell lysis by both complement -de-
pendent  and  antibody-dependent  cell  mediated  cytotoxic-
ity.  In the Randomized Evaluation of Long-term efficacy 
of rituximab (REFLEX) study showed that patients who did 
not respond to previous TNF-inhibitor therapy do respond to 
rituximab [22]. 
Another biologic agent of different class is abatacept, 
which belongs to a new class of selective co-stimulation 
modulators.  It is a recombinant fusion protein comprising 
the extracellular domain of human CTLA4 and a fragment of 
the Fc domain of human IgG1, which has been modified to 
prevent complement fixation. Abatacept, like CTLA4, com-
petes with CD28 for CD80 and CD86 binding and thereby 
can be used to selectively modulate T-cell activation [23].
Other biologic approach in treating RA is by interleu-
kin-1 (IL-1) and IL-6 inhibition. Anakinra, is a recombinant 
human interleukin-1 receptor antagonist and the latest ex-
perience to date is tocilizumab, a humanized monoclonal 
antibody specific for the IL-6 receptor (IL-6R). Currently 
numerous and large controlled trials, tocilizumab has been 
shown to have significant efficacy in patients with RA. The 
first-in-class  IL-6R  inhibiting  monoclonal  antibody  is  the 
ninth biologic agent approved for the treatment of RA and 
may be used alone or in combination with methotrexate or 
other DMARDs [24]. The drug is recently available in the 
United States since January 2010.
There are other new biologic therapies for RA that cur-
rently have progressed to clinical trials.  The evolution of 
knowledge and understanding in immune derangements oc-
curring in RA patients is also leading to novel approaches to 
modify the disease, as reflected in the numerous studies and 
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subsequently the new development of the targeted therapies 
for RA. 
Even though biologics are highly effective and recom-
mended as part of treatment in RA, they are still under prac-
ticed in Malaysia due to their high cost. Physicians probably 
are more willing to use biologics if they are listed in the hos-
pital formulary and if they are affordable to the patients, but 
the current price range is seen to be out of reach for most our 
patients.
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